Human type 3 Creatine Kinase MM Isoenzyme

Name: Human type 3 Creatine Kinase MM Isoenzyme
SKU: DAG278
Rating: 5 (1 reviews)

Human type 3 Creatine Kinase MM Isoenzyme, recombinant protein from P. pastoris

COA

SDS

Datasheet

Summary

Product Overview

CreatineKinase MM (CK-MM) Type 3 Isoenzyme Recombinant. Creatine Kinase MM isoenzymewith identical amino acid sequence to that of the native enzyme. CK-MM is a47 kDa dimeric protein comprised of 2 identical subunits. Purified in theenzymatically active fo

Nature

Recombinant

Tag/Conjugate

Unconjugated

Format

Purified, Liquid

Concentration

Lotspecific. Activity: Lot specific IU/mg total protein, One unit will transferone micromole of phosphate from creatine phosphate to ADP per minute at 37°C.Measured at 340nm as one equimolar amount of NADH produced by coupled reaction

Buffer

Tris-bufferedsaline (TBS), 10mM beta-mercaptoethanol, 50% glycerol, pH 7.0-7.5

Preservative

0.1% Sodium Azide

Storage

2-8°C short term, -20°C long term

Introduction

The protein encoded by this gene is a cytoplasmic enzyme involved in energy homeostasis and is an important serum marker for myocardial infarction. The encoded protein reversibly catalyzes the transfer of phosphate between ATP and various phosphogens such as creatine phosphate. It acts as a homodimer in striated muscle as well as in other tissues, and as a heterodimer with a similar brain isozyme in heart. The encoded protein is a member of the ATP:guanido phosphotransferase protein family.

Antigen Description

Creatinekinase isoenzymes play a central role in energy transduction in tissues withlarge, fluctuating energy demands, such as skeletal muscle, heart, brain andspermatozoa.

Keywords

Creatine kinase-M; creatine kinase M chain; CKMM; M-CK; CKM; Creatine kinase M-type; creatine kinase, muscle; EC 2.7.3.2

Citations

Have you cited DAG278 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Simple mass matrices of neutrinos and quarks consistent with observed mixings and masses

PHYSICS LETTERS B

Authors: Nishiura, Hiroyuki; Fukuyama, Takeshi

Abstract

We propose a simple phenomenological model of quarks-leptons mass matrices having fundamentally universal symmetry structure. These mass matrices consist of democratic and semi-democratic mass matrix terms commonly to the neutrino and the quark sectors and have only eight free parameters. We show that this mass matrix model well reproduces all the observed values of the MNS lepton and the CKM quark mixing angles, the neutrino mass squared difference ratio, and quark mass ratios, with an excellent agreement. The model also predicts delta(l)(CP) = -94 degrees for the leptonic CP violating phase and < m > similar or equal to 0.0073 eV for the effective Majorana neutrino mass. (C) 2015 The Authors. Published by Elsevier B.V.

Hard choices, better outcomes: a review of shared decision-making and patient decision aids around dialysis initiation and conservative kidney management

CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION

Authors: Davis, Janet L.; Davison, Sara N.

Abstract

Purpose of review Patients reaching end-stage kidney disease face difficult decisions, including choosing among renal replacement therapies (RRTs). With an increasingly elderly and frail population, there is growing interest in conservative kidney management (CKM) as a viable alternative to dialysis. Shared decision-making (SDM) is a patient-centered approach to these decisions, in which choices are viewed within the explicitly discussed values and preferences of the patient. Patient decision aids (PDAs) are tools designed to facilitate these discussions. The choice between dialysis and CKM is particularly complex, given the poor prognostication data for CKM. This is an emerging area for PDAs in nephrology. This review highlights care gaps around SDM for dialysis versus CKM, presents current PDAs for making choices about RRTs and CKM and discusses exciting new work around the development of novel PDAs. Recent findings Many PDAs have been created recently, primarily to help with decisions about RRTs. Three new PDAs are in testing phases to aid with the more complex decision of choosing between dialysis and CKM. Summary International nephrology communities are moving toward improved SDM with their patients and PDAs are being developed to facilitate this process.